CYClyde W. Yancy

Clyde W. Yancy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Clyde W. Yancy has a total of 507 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiovascular Health Equity: Time for a New Era of Science, Sociology, and Interventions

    by Dipti Itchhaporia, Clyde W. Yancy, Stacey E. Rosen, Amam C. Mbakwem, Thomas Münzel, Adam Timmis, Christopher Kramer

    Joint Editorial on behalf of the American College of Cardiology, the American Heart Association, the European Society of Cardiology, and the World Heart Federation

  • Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry

    by Brian R. Lindman, Linda D. Gillam, Elizabeth M. Perpetua, Sammy Elmariah, Catherine M. Otto, Marielle Scherrer-Crosbie, Patrick T. O’GAra, Martin B. Leon, Michael Mack, Vinod Thourani, et al.

    BACKGROUND: Undertreatment and delayed treatment of aortic stenosis (AS) are common, both of which are associated with increased mortality. Historically, assessment of quality for AS care has focused on peri- and postprocedural outcomes. The American Heart Association Target: AS registry is the first national registry to provide data and evaluate quality for upstream processes of care for patients with AS. METHODS: Randomly selected patients from 2023 and 2024 with moderate or severe AS from 58 sites in the Target: AS registry were included. The 2 primary quality measures were (1) timely diagnosis (percentage of patients with an echocardiogram consistent with possible severe AS who had all assessments to clarify AS severity and symptoms within 30 days) and (2) timely treatment (percentage of patients with a Class I indication for aortic valve replacement treated within 90 days). Secondary measures included documentation of key echocardiographic parameters in the report, clinical recommendations in the echocardiogram report summary, multidisciplinary heart valve team evaluation, guideline-based performance of multimodality testing, and timely surveillance echocardiograms. RESULTS: Among 8097 patients, 47% were women, 7% Black, 6% Hispanic, and 3% Asian. Timely diagnosis occurred in 54% in 2023, improving to 61% in 2024 ( P =0.027) with gaps caused by lack of timely symptom assessment (23% [2023]; 16% [2024]), lack of stroke volume index (35% [2023]; 18% [2024]), or lack of timely multimodality testing (87% [2023]; 75% [2024]). Among those with a Class I indication for aortic valve replacement, timely treatment occurred in 82% (2023) versus 85% (2024) ( P =NS). Multidisciplinary heart valve team evaluation occurred in 78% (2023) versus 84% (2024) ( P =0.008). Key findings in the echocardiography report were documented in 83% (2023) and 85% (2024) ( P =NS), but a clinical recommendation was included in <10% of the time. Timely surveillance echocardiograms for moderate (2 years) and severe AS (1 year) were not performed in ~40% of patients. CONCLUSIONS: The national American Heart Association Target: AS registry demonstrates opportunities for improvement in timely diagnosis, surveillance, and treatment for patients with AS at participating centers. By providing an infrastructure to measure performance and identify best practices, the Target: AS registry has the potential to elevate and optimize care and patient outcomes.


  • Patient Perspectives in Cardiovascular Research: A Qualitative Study of Barriers, Trust, and Strategies for Inclusive Clinical Trials

    by Stephanie Niño de Rivera, Niurka Suero-Tejeda, Rhonda Monroe, Matthew Tang, Sarah Eslami, Aminah Sallam, Patrick O. Gee, Bjorn Redfors, Clyde Yancy, Mario Gaudino, et al.

    BACKGROUND: Women, Black, and Hispanic patients bear a disproportionate burden of cardiovascular disease yet remain underrepresented in clinical trials. Understanding patient perspectives is essential to developing inclusive recruitment strategies in cardiovascular research. METHODS: The RECHARGE trial (Revascularization Choices Among Underrepresented Groups Evaluation) is an ongoing comparative effectiveness study comparing percutaneous coronary intervention and coronary artery bypass grafting among women, Black, and Hispanic patients. To inform recruitment strategies, we conducted a qualitative study using in-person and virtual focus groups and semistructured interviews. Participants were US adults who identified as Black or Hispanic and had a history of percutaneous coronary intervention, coronary artery bypass grafting, or advanced cardiovascular disease. Interviews were guided by the Social-Ecological Model and analyzed using directed content analysis with a constant comparative approach. RESULTS: The sample included 42 participants (35 women, 7 men); 29 identified as Hispanic and 13 as Black. Barriers and facilitators to trial participation spanned multiple levels of the Social-Ecological Model. At the individual and interpersonal levels, barriers included complex study materials, excessive medical jargon, and mistrust of randomization, with concerns about being assigned a less effective treatment. At community and societal levels, participants cited limited recruitment outreach, lack of culturally and linguistically appropriate materials, and mistrust stemming from historical research injustices. Facilitators included trust in healthcare providers, reassurance regarding treatment appropriateness, and involvement of family or support systems. At the community and societal levels, accessible, visual, and multilingual materials were highlighted to support understanding. Participants emphasized the value of plain language, visual, and multilingual materials, adequate time for shared decision-making, and transparent communication about study goals. CONCLUSIONS: Increasing representation of underrepresented populations in cardiovascular trials requires transparent, accessible communication and trust-centered recruitment strategies. Leveraging trusted healthcare providers and community-based outreach is critical to advancing equity in cardiovascular research. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT06399705 and NCT06399692.


  • Open Access

    Clinical Effectiveness of Sodium‐Glucose Cotransporter‐2 Inhibitors Among Older Patients Hospitalized for Heart Failure With Reduced Ejection Fraction

    by Nicholas Brownell, Nicole Solomon, Stephen J. Greene, Karen Chiswell, Muthiah Vaduganathan, Clyde Yancy, Priscilla Hsue, Boback Ziaeian, Gregg C. Fonarow

    Background: SGLT2 (sodium‐glucose cotransporter‐2) inhibitors (SGLT2i) reduce cardiovascular events in randomized controlled trials of patients with heart failure with reduced ejection fraction (HFrEF), but these trials enrolled outpatient, relatively younger patients (median age 66–67). The effectiveness of SGLT2i in older patients hospitalized for HFrEF in routine US clinical practice is not well studied. Methods: This study included Medicare beneficiaries aged ≥65 years hospitalized for HFrEF and eligible for SGLT2i in Get with the Guidelines–Heart Failure between July 1, 2021 and June 30, 2023. Primary outcomes were 30‐day and 1‐year all‐cause mortality, all‐cause readmission, and HF readmission. Association between SGLT2i and outcomes was assessed with Cox regression and overlap weighting using propensity score estimates. Results: A total of 8847 patients were eligible for but not prescribed SGLT2i at hospital admission (Median age 77; 40% women; median left ventricular EF 28%); 1464 (16.5%) patients were initiated on SGLT2i by discharge. After overlap weighting, SGLT2i initiation was independently associated with lower all‐cause mortality (adjusted hazard ratio [HR], 0.76 [95% CI, 0.67–0.86]), all‐cause readmission (HR, 0.89 [95% CI, 0.81–0.97]), and HF readmission (HR, 0.84 [95% CI, 0.75–0.95]) over 12‐month follow‐up, compared with those not prescribed SGLT2i. Findings were consistent across subgroups based on age, sex, race, ethnicity, diabetes status, chronic kidney disease status, and left ventricular EF. Conclusions: Among older patients hospitalized for HFrEF, SGLT2i initiation by time of discharge was independently associated with reduced all‐cause mortality, all‐cause readmission, and HF readmission. These findings support SGLT2i use to improve postdischarge outcomes among older patients hospitalized for HFrEF in routine US practice.


  • Open Access

    Improving Heart Failure Quality of Care Over the First Twenty Years: The Get With The Guidelines-Heart Failure Program

    by Amber B. Tang, Shen Li, Yilun Li, Juan Zhao, Kathie Thomas, Sabra C. Lewsey, Paul A. Heidenreich, Stephen J. Greene, Larry A. Allen, Mariell Jessup, et al.

    BACKGROUND: The Get With The Guidelines-Heart Failure program is a national quality improvement initiative that was established in 2005 with the goal of improving the quality of care for patients hospitalized with heart failure. METHODS: We examined patient characteristics, adherence to achievement and quality measures, and in-hospital outcomes in patients hospitalized with heart failure among Get With The Guidelines-Heart Failure fully participating hospitals between 2005 and 2024. Measures were applied to eligible patients without documented contraindications. Multivariable regression analysis, adjusting for patient and hospital characteristics, was performed to assess temporal changes in individual measures and outcomes. RESULTS: Over the first 20 years, the Get With The Guidelines-Heart Failure program has grown to include 1 561 093 patient records (median age 73 [62–83], 47.4% women, median ejection fraction 45% [28%–58%]) and 819 participating hospitals. There was significant and sustained improvement in an all-or-none composite achievement metric, with an increase from 76.1% to 88.7% between 2005 and 2024 (adjusted odds ratio, 3.7 [95% CI, 3.5–4.0]; P P <0.001). Meanwhile, prescriptions of new therapies such as angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter-2 inhibitors reached rates of 67.3% and 78.2% in 2024, respectively. Sustained improvements were also seen for other achievement and quality measures, including postdischarge follow-up and prescription of anticoagulation for patients with atrial fibrillation or atrial flutter. Equity of care by social vulnerability index also improved over time for guideline-based therapies such as evidence-based β-blockers and mineralocorticoid receptor antagonists. In contrast, vaccination rates and use of implantable cardioverter defibrillators saw recent decreases. CONCLUSIONS: The Get With The Guidelines-Heart Failure program was associated with sustained improvements in key achievement and quality measures for patients hospitalized with heart failure during its initial 2 decades, with a notable rise in the prescription of guideline-directed medical therapies and rapid implementation of new medications.


  • Open Access

    Variable Association of Neighborhood Deprivation and Race With Postoperative Survival After Coronary Artery Bypass Grafting

    by Justin M. Schaffer, Taylor Pickering, John J. Squiers, Jasjit K. Banwait, Alessandro Gasparini, Michael J. Mack, Clyde W. Yancy, J. Michael DiMaio

    Background: Social determinants of health, including neighborhood deprivation measured by the Area Deprivation Index, are key drivers of disparities in health outcomes, including survival after cardiac surgery. We evaluated whether the association between neighborhood deprivation and survival differs across racial and ethnic groups undergoing coronary artery bypass grafting. Methods: We conducted a retrospective study of 739 335 Medicare beneficiaries who underwent isolated coronary artery bypass grafting between 2008 and 2019. A flexible parametric survival model with time‐dependent effects was implemented to estimate standardized (over demographics, clinical, and procedural characteristics) survival probabilities. Primary end points were differences in 30‐day and 5‐year standardized survival probabilities between beneficiaries from the lowest and highest quintiles of neighborhood deprivation (LDNs and HDNs), stratified by race and ethnicity. Results: Unadjusted median survival was substantially higher among beneficiaries in LDNs compared with HDNs (10.65 [95% CI, 10.55–10.76] versus 9.20 [95% CI, 9.14–9.27] years). In our risk‐adjusted model, the magnitude of this difference varied significantly by race and ethnicity. At 30 days, standardized survival differences between LDNs and HDNs were 1.49% [95% CI, 0.45–2.53] among Asian American or Native Hawaiian/Pacific Islander, 1.06% [95% CI, 0.94–1.19] among White, 0.94% [95% CI,0.583–1.31] among Black, and 0.56% [95% CI, 0.25–0.91] among Hispanic beneficiaries. At 5 years, Asian American or Native Hawaiian/Pacific Islander and White beneficiaries showed the largest standardized survival differences between LDNs and HDNs (8.07% [95% CI, 5.37–10.77] and 5.01% [95% CI, 4.62 –5.39], respectively), whereas Black and Hispanic beneficiaries had smaller differences (2.00% [95% CI, 0.71–3.28] and 1.15% [95% CI, 0.05–2.26], respectively). Conclusions: Although LDN (compared with HDN) residence was associated with improved survival after coronary artery bypass grafting, these survival differences were not equally distributed across race and ethnicity. Policies aiming to reduce socioeconomic disadvantage may yield uneven outcomes unless tailored to the specific challenges faced by different racial and ethnic populations.


  • Open Access

    Introducing the OUTPACE Framework for Health Care Quality Improvement

    by Michele Bolles, Heather M. Alger, Mitchell S.V. Elkind, Howard Haft, Sabra C. Lewsey, Mariell Jessup, Karen E. Joynt Maddox, Chiadi E. Ndumele, Clyde W. Yancy, Christine Rutan, et al.

    Equitable, timely, and evidence-based care remains a central goal across health care ecosystems, yet significant quality gaps, care variability, and health disparities persist. Professional societies, including the American Heart Association, have long developed clinical practice guidelines to provide standardized, evidence-based recommendations across the cardiovascular care continuum. These guidelines are operationalized into quality measures to monitor care, identify gaps, and guide improvement. Professional societies, agencies, and health systems have applied implementation science strategies, such as education, data sharing, and evaluation, to improve care quality and achieve quality measures defined in the clinical practice guidelines. American Heart Association’s Get With The Guidelines programs target inpatient quality measures for stroke, heart failure, atrial fibrillation, resuscitation, and coronary artery disease, complemented by ambulatory quality improvement programs to support seamless care transitions. Decades of Get With The Guidelines implementation have enabled American Heart Association teams and volunteers to refine these programs, improving guideline adherence at local, regional, and national levels. Lessons learned informed the development of the Observe, Uncover, Trial, Personalize, Accelerate, Check, Expand Framework, designed to guide successful quality improvement initiatives. While existing quality improvement frameworks provide structured approaches, many are costly, slow, or siloed, limiting rapid-cycle, data-driven innovation across diverse health systems. The Observe, Uncover, Trial, Personalize, Accelerate, Check, Expand framework addresses these limitations as an adaptable model, applicable across care settings, disease areas, patient populations, system size, budgets, and target end points. Here, we illustrate the Observe, Uncover, Trial, Personalize, Accelerate, Check, Expand framework through 2 recent American Heart Association programs: Target: Aortic Stenosis and the IMPLEMENT-HF initiative, demonstrating its utility in guiding effective, scalable quality improvement.

  • Open Access

    Effect of Concomitant Tricuspid Valve Repair on Clinical and Echocardiographic Outcomes in Patients Undergoing Left Ventricular Assist Device Implantation

    by Olga N. Kislitsina, Sandeep N. Bharadwaj, Tingqing Wu, Rebecca Harap, Jane Kruse, Esther B. Vorovich, Jane E. Wilcox, Clyde W. Yancy, Patrick M. McCarthy, Duc T. Pham

    Objectives: The purpose of this study was to determine whether concomitant tricuspid valve repair (TVr) at the time of left ventricular assist device (LVAD) implantation improves outcomes in patients with ≥moderate tricuspid regurgitation (TR) and to evaluate the prognostic value of preoperative right ventricular (RV) strain. Methods: In a retrospective analysis of 100 LVAD recipients (44 TVr; 56 No-TVr), preoperative (preop) and postoperative (postop) clinical, echocardiographic, and hemodynamic variables, including pulmonary vascular resistance (PVR) and pulmonary artery pulsatility index (PAPI), were analyzed. RV free wall strain (RV-FWS) and RV fractional area change (RV-FAC) were measured by speckle tracking. Early right heart failure (RHF) was modeled with multivariable logistic regression, and 2-year mortality was assessed with Fine–Gray competing risk regression. Preoperative and three-month measurements were compared within each of the 100 patients. Results: Baseline invasive hemodynamics, RV-FWS, and RV-FAC were similar between the TVr and No-TVr groups. TVr at the time of LVAD implantation reduced postoperative TR grade, but it did not improve RV-FWS or RV-FAC at 3 months. The No-TVr patients were more often discharged home and had lower 30-day readmissions. PVR was comparable preoperatively and at 3 months postoperatively. In adjusted analyses, preop PVR, PAPI, and TVr were not independently associated with early RHF, whereas decreased preoperative RV-FWS and lower preop RV-FAC independently predicted higher 2-year mortality. Conclusions: In LVAD recipients with ≥moderate TR, concomitant TVr lowers postoperative TR severity but does not improve early RHF, RV strain-based remodeling, or 2-year mortality. Preoperative RV deformation metrics, rather than preoperative PVR or PAPI, independently predict survival following LVAD implantation with or without TVr.


  • Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension

    by Konstantin A. Krychtiuk, Renato D. Lopes, Victoria A Cargill, Roland Chen, Martin R. Cowie, William C. Cushman, Mitchell S.V. Elkind, Shilpi Epstein, Pushkal P. Garg, Bernard J. Gersh, et al.

    Hypertension is the single most important modifiable risk factor for preventable disability and death worldwide and disproportionately affects socially disadvantaged populations. We face a paradox—blood pressure control is low and recent trends suggest it is even declining, despite the availability of inexpensive and effective therapies. A variety of barriers on the system, patient, and healthcare provider side hinder effective drug-based risk factor management. Clinical inertia represents a major barrier on the clinician side, as well as workload and limited education. Common barriers on the patient side include limited English proficiency, low health literacy, and nonadherence with misaligned incentives, limited resources, lack of structured clinical pathways, and reimbursement issues. New innovations in the field of RNA-targeted therapies and device-based interventions could prevent and potentially even cure diseases previously designated as chronic health conditions, such as hypertension. Such novel therapies could potentially overcome several major barriers to effective treatment, including nonadherence. Drug development of novel, long-acting treatments requires consideration of specific clinical trial design aspects, including safety collection, benefit: risk assessment, the development and assessment of novel, qualitative surrogate end points, such as time-in-therapeutic range, the use of representative trial settings as well as the definition of standard of care in placebo-controlled trials, which should be of reasonably high-quality allowing for credible evaluation of effectiveness. Here, we provide an overview on barriers to effective treatment and a framework for trials assessing novel treatments for cardiovascular disease risk factors, including early and broad implementation programs.


  • Open Access

    Get With The Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead

    by Amber B. Tang, Sabra C. Lewsey, Clyde W. Yancy, Paul A. Heidenreich, Stephen J. Greene, Larry A. Allen, Mariell Jessup, Michele Bolles, Christine Rutan, Natalie Navar, et al.

    The Get With The Guidelines-Heart Failure program was developed in 2005 with the goal of bringing evidence-based guidelines in heart failure management into widespread clinical practice. The program includes workshops, webinars, tool kits, chart abstraction, performance benchmarking, and achievement awards to drive quality improvement at participating hospitals. Two decades after its inception, the program has grown to include over 600 participating institutions across the United States. Linking registry data to Centers for Medicare and Medicaid Services claims has also allowed for the evaluation of longitudinal outcomes. Get With The Guidelines-Heart Failure has helped improve the quality of care for patients and has contributed substantially to the understanding of clinical science and optimal management of heart failure. This narrative review provides an overview of the indelible impact of the Get With The Guidelines-Heart Failure program on quality heart failure care over the past 20 years and highlights future challenges and directions.